Rachel A Perry

US Patent:

20220339121, Oct 27, 2022

Filed:

May 16, 2022

Appl. No.:

17/663586

Inventors:

- New Haven CT, US
Rachel Jamison PERRY - New Haven CT, US

International Classification:

A61K 31/06
A61K 9/00
A61K 9/50
A61K 45/06

Abstract:

The present invention includes a low dose and sustained release formulation of a mitochondrial uncoupling agent The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.

US Patent:

20200352879, Nov 12, 2020

Filed:

Jul 22, 2020

Appl. No.:

16/936316

Inventors:

- New Haven CT, US
Rachel Jamison PERRY - New Haven CT, US

International Classification:

A61K 31/06
A61K 9/00
A61K 9/50
A61K 45/06

Abstract:

The present invention includes a low dose and sustained release formulation of a mitochondrial uncoupling agent The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.

US Patent:

20200246490, Aug 6, 2020

Filed:

Oct 5, 2018

Appl. No.:

16/652892

Inventors:

- New Haven CT, US
Rachel Jamison Perry - Hamden CT, US
Gary Cline - New Haven CT, US
Douglas Rothman - Branford CT, US
Kitt Petersen - East Haven CT, US

International Classification:

A61K 49/10
A61K 49/00
G01N 33/58
G01N 33/66
A61K 9/00

Abstract:

The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method that can be used to noninvasively assess rates of hepatic mitochondrial oxidation (V) and/or pyruvate carboxylase (V) flux in a subject. In certain embodiments, the methods utilize a combined NMR/gas chromatography-mass spectrometry analysis of plasma following infusion of [3-C]lactate and glucose tracer. The method of the invention provides investigators with a tool to non-invasively examine the role of altered hepatic mitochondrial metabolism and study the effects of therapeutic interventions for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes (T2D).

US Patent:

20160199310, Jul 14, 2016

Filed:

Aug 29, 2014

Appl. No.:

14/911322

Inventors:

- New Haven CT, US
Rachel Jamison PERRY - New Haven CT, US

International Classification:

A61K 9/50
A61K 9/00
A61K 31/06

Abstract:

The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (DNP). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.